KetoTV reported on Thursday that Nicolas Tzenios plans to launch a keto clinical trial under a partnership with KGK Science Inc, a contract research organisation.
Hon Prof Dr Nicolas Tzenios is the chairman of medical research hub TRCGEN+. He is the author of 'Nic's Keto Diet', a book which is now available in four languages, and created a Keto postgraduate course that is taught in universities and colleges across the globe. TRCGEN+ sponsors medical research clinical trials including Keto diet effects and a genetic research related to specific genetic cancer treatment approach with Kursk State Medical University.
Through this research programme, Hon Prof Tzenios hopes to prove his 'Friendly LDL Theory', which suggests that in the absence of elevated glucose, low-density lipoprotein (LDL) does not oxidise or form plaque and has anti-inflammatory effects. He believes that elevated glucose, rather than fat, results in the onset of cardiovascular and diet-related diseases.
In addition, Hon Prof Tzenios is applying to patent his Friendly LDL Theory. This concept is inspired by the success of the keto diet, which involves the ingestion of high-fat, low-carb foods. If corroborated, his theory has the potential to greatly impact the realm of dietary science, KetoTV said.
Revier Therapeutics closes EUR6m seed financing and launches operations
Tempus announces receipt of FDA clearance for AI pulmonary hypertension detection product
European Commission grants orphan designation for Lundbeck's asedebart
Hanmi Pharm enters exclusive licensing deal with Genentech for obesity therapy HM17321
Olio Labs reveals study demonstrating AI-driven in vivo platform can predict clinical trial outcomes
Mezzion Pharma Co reports positive results from new in vivo study of udenafil
Incyte's Opzelura approved in European Union for moderate atopic dermatitis
American Regent recalls one lot of Papaverine Hydrochloride Injection due to particulate matter
Galmed announces breakthrough development of SCD1 inhibitor Aramchol for cardiac fibrosis
EQT to acquire biosurgery company Corza Biosurgery
Cirius Therapeutics commences enrolment and dosing for Phase 2 study of CIR-0602K in type 1 diabetes
Thalia Therapeutics acquires Sanmirna and raises GBP2.75m to advance AML RNA therapy